Orgotein (superoxide dismutase): a drug for the amelioration of radiation-induced side effects. A double-blind, placebo-controlled study in patients with bladder tumours

Urol Res. 1978;6(4):255-7. doi: 10.1007/BF00262630.


Orgotein, the drug version of Cu-Zn superoxide dismutases is a new and safe anti-inflammatory agent. Animal experiments have shown that it does not interfere with the tumourolytic effects of radiation or chemotherapy. A double-blind, placebo-controlled study has demonstrated that orgotein injected after each daily irradiation session can be used safely and effectively to ameliorate or prevent the side effects due to high-energy radiation therapy (8,400 or 6,400 rads) of bladder tumours. Orgotein significantly reduced the signs and symptoms both in the bladder and the bowel, indicating that it provides a therapeutic regimen for control of these side effects, which to date could only be treated symptomatically.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Clinical Trials as Topic
  • Cystitis / drug therapy*
  • Cystitis / etiology
  • Diarrhea / drug therapy*
  • Diarrhea / etiology
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Proctitis / drug therapy*
  • Proctitis / etiology
  • Radiation Injuries / drug therapy*
  • Radiation Injuries / prevention & control
  • Radiotherapy, High-Energy / adverse effects*
  • Superoxide Dismutase / therapeutic use*
  • Urinary Bladder Neoplasms / radiotherapy*


  • Superoxide Dismutase